强化阿托伐他汀冲击治疗预防冠脉支架术后再狭窄的临床研究  

Strengthen atorvastatin impact treatment in prevention of restenosis after PCI clinical research

作　　者：乔智力[1] 王媛媛[1] 李艳[1] 杨骄霞[1] 

机构地区：[1]牡丹江医学院附属红旗医院心内科,黑龙江省157011

出　　处：《中国心血管病研究》2013年第8期585-587,共3页Chinese Journal of Cardiovascular Research

摘　　要：目的观察强化阿托伐他汀冲击治疗对患者血清基质金属蛋白酶2（MMP-2）的影响，评价其对冠脉支架术后再狭窄的影响。方法选择288例行冠状动脉内支架术的患者，随机分为治疗组和对照组。治疗组在对照组常规治疗的基础上，强化阿托伐他汀冲击治疗。测定PCI手术前、后两组患者血清MMP-2水平，从而评价其对冠脉支架术后再狭窄的影响。结果两组患者PCI术后24h血清MMP-2水平较术前均有明显升高（尸〈O．05），但治疗组的升高程度明显低于对照组（P〈0．05），说明血管内皮损伤可使血清MMP-2水平明显升高，而强化阿托伐他汀冲击治疗可以抑制血清MMP-2的表达。经强化阿托伐他汀冲击治疗后，患者术后再狭窄的发生概率明显低于对照组，差异有统计学意义（P‘〈0．05）。结论强化阿托伐他汀冲击治疗，可以有效降低PCI术后患者血清PPM-2水平，从而有效预防术后支架内再狭窄的发生。Objective To observe the impact of strengthening atorvastatin on serum MMP-2, thereby eval- uating PCI restenosis after it. Methods 288 cases of PCI patients were randomly divided into treatment group and control group. In treatment group, the patients were given strengthen atorvastatin on the basis of control group. Serum levels of MMP-2 was measured before and after of PCI surgery and investigated the relationship with restenosis. Results Two groups of patients serum MMP-2 levels in the 24 hours were significantly higher than PCI preoperative（P〈 0.05 ）. But the treatment group increased lower than the control group（P〈0.05 ）, description vas- cular endothelial injury serum MMP-2 levels were significantly increased. While strengthening atorvastatin therapy can suppress serum MMP-2 expression. Enhanced atorvastatin treatment, postoperative restenosis was significantly lower than the control group （P〈0.05）. Conclusion Strengthen atorvastatin treatment can effectively reduce PCI postoperative serum levels of PPM-2 and then prevent restenosis after PCI.

关 键 词：阿托伐他汀 冲击治疗 血清基质金属蛋白酶2 再狭窄 

分 类 号：R589[医药卫生—内分泌]